0001209191-21-020266.txt : 20210312
0001209191-21-020266.hdr.sgml : 20210312
20210312175440
ACCESSION NUMBER: 0001209191-21-020266
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210310
FILED AS OF DATE: 20210312
DATE AS OF CHANGE: 20210312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Socks David A
CENTRAL INDEX KEY: 0001378847
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 21738952
MAIL ADDRESS:
STREET 1: C/O CADENCE PHARMACEUTICALS, INC.
STREET 2: 12481 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-10
0
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001378847
Socks David A
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PAK
NJ
07932
1
0
0
0
Common Stock
2021-03-10
4
S
0
2425
48.3163
D
1433520
I
David A. Socks 2013 Revocable Trust
Common Stock
2021-03-10
4
S
0
7844
49.0203
D
1425676
I
David A. Socks 2013 Revocable Trust
Common Stock
2021-03-10
4
S
0
1802
49.9303
D
1423874
I
David A. Socks 2013 Revocable Trust
Common Stock
2021-03-11
4
S
0
41698
47.1809
D
1382176
I
David A. Socks 2013 Revocable Trust
Common Stock
2021-03-11
4
S
0
731
47.5367
D
1381445
I
David A. Socks 2013 Revocable Trust
Common Stock
2021-03-12
4
S
0
500
46.67
D
1380945
I
David A. Socks 2013 Revocable Trust
Common Stock
103.49
I
By 401(k) Plan
All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.53 to $48.52. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.53 to $47.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.57 to $50.29. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $47.67. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Larry Miller, Attorney-in-Fact for David A. Socks
2021-03-12